# US 11,298,517 B2 · Advanced functional biocompatible foam used as a hemostatic agent for non-compressible acute wounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,517 B2
- Document ID: US11298517B2
- Status: Granted
- Kind: B2
- Application number: 16/251,553
- Filed: 2019-01-18
- Published: 2019-06-27
- Granted: 2022-04-12
- Earliest claimed: 2009-11-13
- Assignees: University of Maryland, College Park
- Applicants: University of Maryland, College Park
- Inventors: Matthew Dowling; Srinivasa R. Raghavan
- Web page: https://patentgrep.com/patent/US11298517B2

## CPC

- A61M 35/003: {Portable hand-held applicators having means for dispensing or spreading integral media (hand-held massage devices with liquid delivery A61H7/003)}
- A61L 24/0026: {Sprayable compositions}
- A61L 26/0076: {Sprayable compositions}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/04: Antibacterial agents
- A61L 2400/04: Materials for stopping bleeding
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.

## Claims

### Claim 1

A method for treating a cavity wound including a non-compressible hemorrhage, comprising applying a hydrophobically-modified chitosan composition to a cavity wound including a non-compressible hemorrhage, wherein:
the hydrophobically-modified chitosan composition does not comprise proteins involved in the accelerated formation of fibrin networks, and the composition comprises a foaming agent to foam and expand in the cavity and effect hemostasis with the hydrophobically modified chitosan; the hydrophobically-modified chitosan comprising hydrophobic substituents having from 8 to 24 carbon atoms so as to form a gel-like hemostatic network.

### Claim 2 (depends on 1)

The method of claim 1, wherein the foaming agent is selected from sodium lauryl sulfate and sodium oleate.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition further comprises one or more plasticizers selected from glycerol, glycerophosphate, polyethylene glycol, polyethylene oxide, tripolyphosphate, polycaprolactone, polyurethane, and silicone.

### Claim 4 (depends on 3)

The method of claim 3, wherein hydropobically modified chitosan composition has a ratio of chitosan:plasticizer of 80:20 by weight.

### Claim 5 (depends on 1)

The method of claim 1, wherein the hydrophobic substituents are alkanes.

### Claim 6 (depends on 1)

The method of claim 1, wherein the hydrophobically modified chitosan has a concentration of 0.1% to 2.0% by weight.

### Claim 7 (depends on 1)

The method of claim 1, wherein the hydrophobic modification of the chitosan is of 1 to 100 moles of a hydrophobic substituent per 1 mole of Chitosan.

### Claim 8 (depends on 1)

The method of claim 1, wherein the hydrophobically modified composition further comprises one or more anti-bacterial compounds selected from ampicillin, penicillin, bactroban, bacitracin, mupirocin, neomycin, vanomycin, ponericin G1, norfloxacin, and silver.